MDMalika I. Denieva

Malika I. Denieva

*This is an algorithmically generated author record based on publicly available information.

Malika I. Denieva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cutis Verticis Gyrata Differential Diagnosis: Clinical Case

    by Tatiana S. Belysheva, Ekaterina E. Zelenova, Tatiana A. Gassan, Eduard T. Ambarchyan, Malika I. Denieva, Yana V. Vishnevskaya, Tatiana V. Nasedkina, Nikolay N. Murashkin

    Background. Cutis verticis gyrata is rare benign scalp disorder characterized by excessive skin and subcutaneous tissue proliferation and hypertrophy. Nowadays, there are three forms of this disease with various developmental mechanisms and associated manifestations. Clinical case description. This article presents the patient admitted with diagnosis and clinical picture of pachydermia, who underwent surgical excision of scalp abnormal tissues. However, the diagnosis of giant congenital melanocytic nevus was established according to the results of clinical examination. Later it was confirmed by histological and immunohistological studies. Moreover, pathogenic variants in the NRAS gene were not revealed. Conclusion. This case demonstrates the complexity of differential diagnosis of pachydermia that leads to careful examination of patients with morphogenetic studies of affected tissues samples.

  • Open Access

    Skin microbiome in patients with acne

    by E. V. Dvoriankova, M. I. Denieva, Z. R. Khismatullina

    In the past few years, our formulation of the role of Cutibacterium acnes in the pathophysiology of acne has undergone a paradigm shift. According to modern concepts, this disease is caused by not C. acnes hyperproliferation, but an imbalance between various phylotypes of this microorganism that develops due to changes in the skin microbiome composition.Antibiotics are medicines that are usually used to treat this disease. However, the need to use them for a long time, which causes skin dysbacteriosis, increasing resistance to antibiotics, as well as new understanding of the pathophysiology of acne encourage to change the direction of acne treatment. The use of topical benzoyl peroxide and antibiotic combination products not only improves the effectiveness of therapy, especially for inflammatory acne, but also prevents the development of antibiotic resistant pathogenic microflora. Benzoyl peroxide is a lipophilic substance that concentrates in the skin inside the sebaceous hair follicles, producing benzoic acid and reactive oxygen species. Benzoyl peroxide as an oxidizing agent can suppress the synthesis of proteins and nucleotides, activities of mitochondria in microorganisms through inhibiting their growth and reproduction. The combination of this component and antibiotics contributes to the synergy of their action, and effectively reduces inflammation and acne. As examples, we present the clinical case reports of a 20-year-old patient S., who complained of rashes on the facial skin at puberty, as well as an 18-year-old patient A. with rashes on her face. These cases showed that the topical drug was well tolerated, and the only undesirable side effect reported was a feeling of skin tightness.


  • Open Access

    Infectious complications of atopic dermatitis

    by E. V. Dvoriankova, M. I. Denieva, G. А. Shevchenko

    Atopic dermatitis is a chronic inflammatory skin disease linked to a genetic predisposition and accompanied by acute inflammatory manifestations that develop due to abnormality of skin barrier properties and changes in both innate and adaptive immune responses. The high risk of developing complications of this disease caused by skin and systemic infections is one of the most urgent problems of modern health care. However, infectious complications of atopic dermatitis may include skin and soft tissue infections, herpetic eczema, bacteremia, osteoarthritis, myelitis, septic arthritis, and endocarditis. Skin barrier defects, type 2 immune-mediated inflammation, Staphylococcus aureus colonization, and skin dysbiosis are main predisposing factors for an increased incidence of infectious complications of atopic dermatitis. The development of infectious complications of atopic dermatitis may be prevented by comprehensive treatment of exacerbations of the underlying disease, sanitation of chronic infection foci, as well as restoration and maintenance of the skin barrier function. The use of special moisturizers and emollients for skin care during exacerbation and remission is an important and integral part of therapeutic and preventive measures.Emollients are medical cosmetic products that are close to the natural lipid skin barrier in composition. They not only effectively soften and moisturize the skin, but also restore damaged protective properties. Additional components of emollients with anti-inflammatory and antimicrobial activity are an optional, but desirable condition to prevent recurrence of the disease and reduce the risk of developing a secondary infection. Thus, not only special skin care drugs, but also products for patients with atopic dermatitis, can contribute to the development of antibacterial protection and prevent the development of infectious complications.